INTRODUCTION
High-dose melphalan therapy plus autologous stem-cell transplantation (HDT-ASCT) is a standard of care for previously untreated multiple myeloma (MM) patients age Յ 65 years and results in a median overall survival (OS) of 4 to 6 years. [1] [2] [3] [4] Tandem transplantation offers better outcome than single transplantation in patients not achieving a complete response/near complete response (CR/nCR) 2 or at least very good partial response (VGPR) after first transplantation. 4 Overall, in the context of transplantation, achievement of CR or VGPR is associated with improved
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progression-free survival (PFS) and OS. 5, 6 Achievement of CR or at least VGPR therefore represents a major objective of treatment for previously untreated MM. 7, 8 Historically, vincristine, doxorubicin, and dexamethasone (VAD) has been a standard for induction therapy before HDT-ASCT 2, 4, [9] [10] [11] [12] ; however, it typically results in CR rates Ͻ 10%. [10] [11] [12] [13] More active induction regimens may result in increased at least VGPR rates, leading to increased at least VGPR rates post first transplantation and improved long-term outcomes. Moreover, improving at least VGPR rates post first transplantation could obviate the need for a second transplantation in an increased number of patients. 2, 4 The novel agents bortezomib, thalidomide, and lenalidomide have demonstrated substantial activity in both previously untreated and relapsed MM, with high rates of response and at least VGPR in combination with standard MM agents and regimens.
14, 15 Furthermore, the introduction of novel agents in first-line therapy has improved PFS and OS in the nontransplantation setting. 16, 17 An Intergroupe Francophone du Myélome (IFM) phase II study investigated bortezomib plus dexamethasone as induction before transplantation in 48 patients with previously untreated MM. 18 The response rate was 67%, including 21% CR/nCR and 31% at least VGPR. This translated into a 55% post-transplantation at least VGPR rate. Toxicities were generally mild to moderate and proved manageable; there was no treatment-related mortality. 18 Other studies of induction with bortezomib and dexamethasone have shown similarly high levels of activity.
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The IFM therefore conducted this phase III study to compare the efficacy and safety of VAD and bortezomib plus dexamethasone as induction therapy before HDT-ASCT and to evaluate the impact of postinduction consolidation therapy. The study aimed to determine whether bortezomib plus dexamethasone resulted in a higher postinduction CR/nCR rate compared with VAD and whether this produced improved response rates and outcomes post-transplantation.
PATIENTS AND METHODS

Patients
Eligible patients were age Յ 65 years and had untreated symptomatic MM with measurable paraprotein in serum (Ͼ10 g/L) or urine (Ͼ 0.2 g/24 h). Key inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status Յ 2, life expectancy Ն 2 months, and adequate renal (no end-stage renal failure requiring dialysis), hematologic (platelets Ն 50 ϫ 10 9 /L, neutrophils Ն 0.75 ϫ 10 9 /L), and hepatic (bilirubin Յ 3ϫ upper limit of normal, AST and ALT Յ 4ϫ upper limit of normal) function. Key exclusion criteria included confirmed amyloidosis, HIV positivity, history of other malignancy (other than basal cell carcinoma and carcinoma of the cervix in situ), uncontrolled diabetes, and grade Ն 2 peripheral neuropathy (National Cancer Institute Common Toxicity Criteria [NCI-CTC] v2.0). All patients provided written informed consent. The study was approved by the relevant national health authority agency and the Ethics Committee of the University of Nantes and was conducted in accordance with the International Conference on Harmonization guidelines on Good Clinical Practice and the principles of the Declaration of Helsinki.
Study Design
This open-label phase III study was conducted at 89 sites in France, Belgium, and Switzerland between August 9, 2005, and January 18, 2008. Data cutoff date for this report was June 5, 2009 . Patients were centrally randomly assigned (1:1:1:1) to receive VAD plus no consolidation (arm A1), VAD plus dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) consolidation (arm A2), bortezomib plus dexamethasone with no consolidation (arm B1), or bortezomib plus dexamethasone plus DCEP consolidation (arm B2). Randomization was stratified by baseline ␤ 2 -microglobulin (Ͼ 3 v Յ 3 mg/L) and presence of chromosome 13 abnormalities by fluorescent in situ hybridization analysis.
VAD comprised four 4-week cycles of vincristine 0. Dose modifications were required for specified hematologic and nonhematologic adverse events (AEs). Patients with febrile neutropenia during induction had treatment discontinued until fever abated; treatment was discontinued for any grade 4 hematologic toxicity until neutrophils were Ͼ 0.75 ϫ 10 9 /L and platelets were Ͼ 50 ϫ 10 9 /L. Bortezomib-associated peripheral neuropathy was managed according to established guidelines.
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For all other study drug-related grades 3 and 4 AEs, the agent responsible was withdrawn until complete recovery and was reinitiated at a reduced dose.
Assessments
The primary end point was postinduction CR/nCR rate. The study started before publication of the international uniform criteria, 24 which incorporated nCR within VGPR; we therefore also report at least VGPR rate as a relevant efficacy parameter. Secondary end points included postinduction overall response rate, CR/nCR rate with and without DCEP consolidation, CR/nCR and at least VGPR rates post first transplantation, proportions of patients requiring a second transplantation, and safety and toxicity of induction.
Response was evaluated by investigators according to modified European Group for Blood and Marrow Transplantation (EBMT) criteria, 25 including additional categories of nCR (CR but immunofixation-positive) 26 and VGPR (serum M-protein reduction Ն 90%; urine light chain Ͻ 100 mg/24 h). 24 Responses were determined postinduction, post-DCEP, and after first and second transplantation; response assessments were confirmed by an independent review committee. Blood and 24-hour urine samples were taken at baseline, before each induction/consolidation cycle, 4 weeks after the last induction/consolidation cycle, at transplantation, and 1 to 3 months posttransplantation. In patients with 100% M-protein reduction by electrophoresis, determination of CR required immunofixation and bone marrow examination. EBMT criteria require response confirmation after 6 weeks; however, transplantation was not delayed to confirm postinduction/consolidation response. AEs were graded by NCI-CTC v2.0.
Statistical Analysis
Approximately 480 patients were to be enrolled to ensure 440 patients for analysis (110 in each arm; 220 receiving VAD or bortezomib plus dexamethasone induction). This provided 80% power (two-sided ␣ ϭ .05) to detect a 10% difference in CR/nCR rate postinduction, assuming rates of 20% with bortezomib plus dexamethasone and 10% with VAD. It also provided 80% power (two-sided ␣ ϭ .05) to demonstrate a 15% CR/nCR benefit with the addition of DCEP consolidation to VAD (10% to 25%) or bortezomib plus dexamethasone (20% to 35%).
Comparisons of response rates between patients receiving VAD or bortezomib plus dexamethasone, including the primary efficacy analysis of CR/ nCR rate, were performed using a 2 test, as were comparisons of response rates between patients receiving or not receiving DCEP. Comparisons of time-to-event data were performed using the log-rank test; distributions were estimated using Kaplan-Meier methodology. PFS was defined as time from treatment start to progression, relapse, or death. Safety was evaluated in all patients who received at least one dose of study drug. Rates of AEs were compared between patients receiving VAD or bortezomib plus dexamethasone using the Cochran-Mantel-Haenszel 2 test adjusted for stratification factors.
RESULTS
Patient Characteristics and Disposition
A total of 493 patients were enrolled, and 482 were randomly assigned; 242 received VAD induction (121, A1; 121, A2) and 240 received bortezomib plus dexamethasone (121, B1; 119, B2). Patient disposition and flow through the protocol is shown in Figure 1 . Baseline characteristics are summarized in Table 1 . No significant differences were seen between groups. Overall, 57.5% of patients had 27 stage III myeloma; 42.3% had chromosome 13 deletion by fluorescent in situ hybridization. In the VAD and bortezomib plus dexamethasone groups, t(4;14) and/or del(17p) were seen in 12.0% and 16.7% of patients, respectively (P ϭ .14).
Response to Induction and Consolidation
The evaluable population included 441 patients, 218 who received VAD (110, A1; 108, A2) and 223 who received bortezomib plus dexamethasone (112, B1; 111, B2); the reasons for exclusion of 24 and 17 patients, respectively, are shown in Figure 1 . Postinduction CR/ nCR rate was significantly higher following induction with bortezomib plus dexamethasone versus VAD (14.8% v 6.4%; P ϭ .004); similarly, at least VGPR (37.7% v 15.1%; P Ͻ .001) and overall response rates were significantly higher ( Table 2) .
Significantly higher at least VGPR rates and consistently higher CR/nCR rates were seen with bortezomib plus dexamethasone versus VAD regardless of ISS disease stage and in patient subgroups defined by cytogenetic abnormalities ( Table 2 ). The at least VGPR and CR/ nCR rates were similar with bortezomib plus dexamethasone for patients with stage I, II, or III disease, whereas rates with VAD decreased with increasing disease stage. The at least VGPR and CR/nCR rates with bortezomib plus dexamethasone appeared somewhat higher in patients with del(13) versus no del(13) and were similar among patients with or without t(4;14) and/or del(17p).
Among the evaluable population, following induction with or without consolidation, CR/nCR (14.0% v 15.1%; P ϭ .720) and at least VGPR (28.4% v 32.0%; P ϭ .371) rates were similar in patients who were to receive DCEP (A2 ϩ B2, n ϭ 219) or not (A1 ϩ B1, n ϭ 222), by intent-to-treat analysis. Among patients who actually received DCEP (91, A2; 96, B2), CR/nCR and at least VGPR rates were 8.0% and 22.2% in A2 (v 8.2% and 15.4% in A1) and 26.0% and 50.0% in B2 (v 19.6% and 41.1% in B1). The at least VGPR rate was thus superior with bortezomib plus dexamethasone with no consolidation (B1) compared with VAD plus DCEP (A2).
Stem-Cell Mobilization and Transplantation
Stem cell yields of Ͼ 2 ϫ 10 6 CD34 ϩ cells/kg were achieved by 98% and 96% of VAD and bortezomib plus dexamethasone patients, respectively. Full data regarding stem-cell collection will be reported in depth elsewhere (Moreau et al, manuscript in preparation).
A total of 184 (84.4%) of 218 and 197 (88.3%) of 223 evaluable patients who received VAD and bortezomib plus dexamethasone induction, respectively, underwent transplantation. Posttransplantation response rates among the evaluable population are shown in Table 3 . Post first transplantation, CR (16.1% v 8.7%; P ϭ .016), CR/nCR (35.0% v 18.4%; P Ͻ .001), and at least VGPR (54.3% v 37.2%; P Ͻ .001) rates were significantly higher among patients who received bortezomib plus dexamethasone versus VAD. Overall, including responses post second transplantation, CR/nCR (39.5% v 22.5%; P Ͻ .001) and at least VGPR (67.7% v 46.7%; P Ͻ .001) rates, respectively, were again significantly higher.
Among patients in whom transplantation was actually performed, overall response rate post first transplantation was 90.9% and 91.3% (P ϭ .921) in patients who received bortezomib plus dexamethasone and VAD, respectively, and CR (18.3% v 10.3%; P ϭ .020), CR/nCR (39.6% v 21.7%; P Ͻ .001), and at least VGPR (61.4% v 44.0%; P ϭ .001) rates were significantly higher following bortezomib plus dexamethasone versus VAD. Consequently, per protocol, fewer patients who received bortezomib plus dexamethasone along with first transplantation (76 [38.6%] of 197 patients) were deemed to require a second transplantation versus the VAD group (103 [56%] of 184; P ϭ .001); however, of these patients, only 41 (20.8%) and 50 (27.2%), respectively, actually received a second transplantation.
Subsequent Therapy
Post transplantation, 153 patients each from the VAD and bortezomib plus dexamethasone groups received further treatment; 127 (83.0%) and 140 (91.5%), respectively (P ϭ .026), were enrolled onto protocol IFM 2005-02 and received lenalidomide consolidation before random assignment to lenalidomide maintenance or placebo. Additionally, four patients (2.9%) from each group received lenalidomide maintenance, and 15 (10.2%) VAD and eight (5.3%; P ϭ .116) bortezomib plus dexamethasone patients received thalidomide maintenance. Outcomes Figure 2 shows PFS and OS in all 482 patients according to induction therapy received. The median PFS was 29.7 months among patients who received VAD versus 36.0 months among patients who received bortezomib plus dexamethasone induction, with 128 (52.9%) of 242 and 110 (45.8%) of 240 patients, respectively, having progressed (P ϭ .064, or P ϭ .057 if adjusted for initial stratification factors) after median follow-up of 31.2 months. Median OS has not been reached in either group after median follow-up of 32.2 months, with 45 (18.6%) of 242 patients in the VAD group and 40 (16.7%) of 240 patients in the bortezomib plus dexamethasone group having died (P ϭ .508, or P ϭ .572 if adjusted for initial stratification factors); respective 3-year OS rates were 77.4% and 81.4%.
Safety
The safety population comprised 239 patients in the VAD group (910 cycles) and 239 patients in the bortezomib plus dexamethasone group (930 cycles). Safety profiles during induction, including the most common hematologic and nonhematologic toxicities, are summarized in Table 4 . Grade 3 to 4 anemia, neutropenia, and thrombosis were significantly more frequent in the VAD group. Seven deaths related to toxicity (2.9%) were recorded in the VAD group versus none in the bortezomib plus dexamethasone group (P ϭ .02).
During induction, consolidation, and first transplantation, peripheral neuropathy (encompassing multiple AEs; Table 4 double-dagger footnote) was reported in 77 (32.2%) and 126 (52.7%; P Ͻ .001) patients who received VAD and bortezomib plus dexamethasone, respectively. Rates of grade 2 (10.5% v 20.5%; P ϭ .003) and grade 3 to 4 (2.5% v 9.2%, P ϭ .002) peripheral neuropathy were significantly higher in the bortezomib plus dexamethasone group.
Overall, 12 patients (seven infection, three hemorrhage, two progression) in the VAD group and two patients (one infection, one progression) in the bortezomib plus dexamethasone group died during protocol treatment, including seven and one during induction, one and zero during consolidation, and four and one during either transplantation, respectively.
DISCUSSION
The results of this IFM randomized phase III study demonstrate that among previously untreated MM patients age Յ 65 years, induction therapy with bortezomib plus dexamethasone significantly improved both postinduction and post-transplantation rates of CR/ nCR and at least VGPR compared with VAD, previously the standard of care in this setting. Notably, the at least VGPR rate achieved following the first transplantation in the bortezomib plus dexamethasone group is comparable with rates achieved after tandem transplantation in other studies. 4, 9, 10, 12 Importantly, bortezomib plus dexamethasone was equally effective in patients with high-risk MM, including those with ISS stage III disease and poorrisk cytogenetic abnormalities. On intent-to-treat analysis of all NOTE. All response assessments were confirmed by an independent review committee. Abbreviations: VGPR, very good partial response; CR/nCR, complete response/near CR; VAD, vincristine plus doxorubicin plus dexamethasone; A1, VAD plus no consolidation; A2, VAD plus dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) consolidation; B1, bortezomib plus dexamethasone (BD) with no consolidation; B2, BD plus DCEP consolidation; ORR, overall response rate; PR, partial response; MR, minimal response; SD, stable disease; PD, progressive disease. response-evaluable patients, use of DCEP consolidation postinduction did not have a significant impact on response rates. In patients who actually received DCEP, the benefit of adding consolidation to bortezomib plus dexamethasone was only marginal (50% v 41%, at least VGPR), and bortezomib plus dexamethasone with or without DCEP was superior to VAD plus DCEP, suggesting that such additional treatment pretransplantation is not warranted.
Our data indicate that the better response rates postinduction and post-transplantation with bortezomib plus dexamethasone versus VAD translated into a trend toward longer PFS. It is important to note that this study was not designed to evaluate PFS and that the trend toward longer PFS in favor of the bortezomib plus dexamethasone group was seen despite slight imbalances between the groups, potentially favoring the VAD group in terms of improved PFS in the proportions of patients with poor-risk cytogenetics and the proportions of patients receiving a second transplantation. In addition, in randomized studies such as ours, it may be difficult to assess the impact of induction treatment on PFS when patients receive different posttransplantation treatment. Regarding OS, no significant difference is apparent after median follow-up of 32.2 months, and the number of deaths is too low to draw any statistically valid conclusions, as might be expected in this population in which median OS is 5 to 6 years. [1] [2] [3] [4] OS comparisons may also be confounded by the effect of subsequent therapy.
Bortezomib plus dexamethasone appeared generally well tolerated, reflecting our phase II experience, 18 with zero deaths related to toxicity versus seven deaths related to toxicity in the VAD group within the four induction cycles. With bortezomib, there were significantly higher incidences of grades 2 to 4 peripheral neuropathy from induction through first transplantation compared with those in the VAD group. Nevertheless, these rates appeared similar to those reported in other studies of bortezomib alone or in combination.
18,21,22,28-31 Additionally, other studies of bortezomib plus dexamethasone have shown this toxicity to be reversible in the majority of patients.
18,32 When bortezomib is given in combination with dexamethasone or with chemotherapy, lower doses (1.0 mg/m 2 v 1.3 mg/m 2 ) or weekly administration of bortezomib may be associated with a lower incidence of peripheral neuropathy, while retaining substantial, although possibly somewhat reduced, efficacy.
22,30,32-34 Finally, 96% of patients treated with bortezomib plus dexamethasone yielded sufficient CD34 ϩ cells to undergo at least one transplantation, although stem-cell collection was primed with G-CSF only.
The response rates with VAD in our study appear comparable to those in previous reports, 4 ,35 while response rates with bortezomib plus dexamethasone appear favorable or comparable to those from randomized studies of other novel-agent-plus-dexamethasone induction regimens. In two phase III studies, thalidomide plus dexamethasone resulted in an overall response rate of 63% and CR rates of 4% to 7.7%, 36,37 with one study reporting an at least VGPR rate of 43.8% after a median duration of therapy of 6.9 months. 37 In a study of thalidomide plus dexamethasone versus VAD, the postinduction at least VGPR rates were 24.7% versus 7.3% (P ϭ .0027); however, this difference was lost post-transplantation, with at least VGPR rates increasing to 44.4% and 41.7% (P ϭ .87), respectively. 38 In the ECOG E4A03 phase III study of lenalidomide plus high-dose or low-dose dexamethasone, 39 overall response rates of 79% and 68%, respectively, were reported after four cycles of induction. Preliminary results from phase III studies of triplet induction regimens including bortezomib, doxorubicin, and dexamethasone
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; cyclophosphamide, thalidomide, and dexamethasone
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; and thalidomide,doxorubicin, and dexamethasone 35 seem to show similar response rates to those achieved with bortezomib plus dexamethasone. In contrast, response †No antiviral prophylaxis for herpes zoster was specified in the protocol. ‡The following Medical Dictionary for Regulatory Activities (MedDRA) -preferred terms used by investigators were considered related to neurologic toxicity by the principal investigator and included in the totals for peripheral neuropathy: accommodation disorder, anosmia, areflexia, difficulty in walking, dysesthesia (no essential change), fall, formication, hypoesthesia, hyporeflexia, muscle spasms, neuralgia (not otherwise specified ͓NOS͔), neuralgic amyotrophy, neurologic disorder NOS, pain in limb, paraparesis, paresthesia, peripheral neuropathy aggravated, peripheral motor neuropathy, peripheralrates appeared higher in two phase III studies of bortezomib, thalidomide, and dexamethasone (VTD), 28,42 and in early-phase studies of bortezomib, lenalidomide, and dexamethasone 43, 44 ; however, only randomized studies versus bortezomib plus dexamethasone would be able to confirm this.
In conclusion, bortezomib plus dexamethasone should now be considered a standard induction treatment before transplantation to which other regimens, including novel agents, should be compared. Triplet combinations using lower bortezomib doses might be as effective and better tolerated. An ongoing randomized trial (IFM 2007-02) 45 is evaluating bortezomib plus dexamethasone versus a VTD regimen employing bortezomib 1.0 mg/m 2 and thalidomide 100 mg dosing. 
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